Sulforaphane activates CD8 + T cells antitumor response through IL-12RB2/MMP3/FasL-induced MDSCs apoptosis’
Journal for ImmunoTherapy of Cancer · 2024
DOI: 10.1136/jitc-2023-007983 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2024. Verfasst von Jinyan Liu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Biotherapy Center and Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China. Hauptthemen laut MEDLINE: Myeloid-Derived Suppressor Cells, Sulfoxides, Isothiocyanates. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: the National Natural Science Foundation of China, Innovation Team within the First Affiliated Hospital of Zhengzhou University, Henan Province Science and Technology Research.
Abstract (Originalsprache)
Background
Extensive attention has been given to the role of myeloid-derived suppressor cells (MDSCs) in driving tumor progression and treatment failure. Preclinical studies have identified multiple agents that eliminate MDSCs. However, none have been authorized in the cliniccal ues due to the safety reasons. In the present study, we investigated the efficacy and mechanism of sulforaphane (SFN) to eliminate MDSCs in the tumor microenvironment (TME).
Methods
We monitored SFN effect on tumor growth and the percents or apoptosis of immune cell subsets in mice models bearing LLC or B16 cells. Flow cytometry, quantitative reverse transcription-PCR, immunohistochemistry, ELISA, immunofluorescence, imaging flow cytometry and western blot were performed to validate the role of SFN on MDSCs function in vivo and in vitro. RNA sequencing was then used to interrogate the mechanisms of how SFN regulated MDSCs function. Tumor xenograft models were established to evaluate the involvement of IL-12RB2/MMP3/FasL induced MDSCs apoptosis in vivo. We verified the effect of SFN on MDSCs and CD8 + T cells in the blood samples from a phase I clinical trial (KY-2021–0350).
Results
In this study, we elucidated that SFN liberated CD8 + T-cell antitumor ability by reducing MDSCs abundance, leading to repressed tumor growth. SFN treatment suppressed MDSCs accumulation in the peripheral blood and tumor sites of mice, but had no effect on the bone marrow. Mechanistically, SFN activates IL-12RB2, which stimulates the MMP3/FasL signaling cascade to trigger caspase 3 cleavage and induce apoptosis in MDSCs. Clinically, SFN treatment eliminates peripheral MDSCs and increases the percentage and activation of CD8 + T cells.
Conclusions
Collectively, we uncovered the role of SFN in eliminating MDSCs to emancipate CD8 + T cells through IL-12RB2/MMP3/FasL induced apoptosis, thus providing a strategy for targeting MDSCs to control tumors and improve clinical efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Biotherapy Center and Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
- Department of Medical Record Management and Statistics, Shandong Provincial, Qianfoshan Hospital, The First Affiliated Hospital of Shandong First Medical University, Jinan, China.
- Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
- Department of Nutrition and Food Hygiene, College of Public Health, and the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China yizhang@zzu.edu.cn lqjnutr@zzu.edu.cn.
- Biotherapy Center and Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China yizhang@zzu.edu.cn lqjnutr@zzu.edu.cn.
- State Key Laboratory of Esophageal Cancer Prevention & and Treatment, Zhengzhou, Henan, China.
Förderung
- the National Natural Science Foundation of China
- Innovation Team within the First Affiliated Hospital of Zhengzhou University
- Henan Province Science and Technology Research
- Henan Province Major Public Welfare Projects
- Healthy Talents Project of Henan Province
- State's Key Project of Research and Development Plan
- Henan Province Medical Science and Technology Research Provincial and Ministry Co-constructed Projects
- Henan Provincial Central Leading Local Science and Technology Development Fund Project
Zitieren
APA
Liu, J., Chen, H., Guo, C., Li, J., Li, M., Zhao, M., Fu, Z., Zhang, Z., Li, F., Zhao, X., Yang, L., Wang, L., Lv, Q., & Zhang, Y. (2024). Sulforaphane activates CD8 + T cells antitumor response through IL-12RB2/MMP3/FasL-induced MDSCs apoptosis’. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2023-007983
Vancouver
Liu J, Chen H, Guo C, Li J, Li M, Zhao M, et al. Sulforaphane activates CD8 + T cells antitumor response through IL-12RB2/MMP3/FasL-induced MDSCs apoptosis’. Journal for ImmunoTherapy of Cancer. 2024. doi:10.1136/jitc-2023-007983
BibTeX
@article{Liu2024,
author = {Liu, Jinyan and Chen, Huanan and Guo, Caijuan and Li, Jieyao and Li, Miaomiao and Zhao, Ming and Fu, Ziyi and Zhang, Zhen and Li, Feng and Zhao, Xuan and Yang, Li and Wang, Liping and Lv, Quanjun and Zhang, Yi},
title = {Sulforaphane activates CD8 + T cells antitumor response through IL-12RB2/MMP3/FasL-induced MDSCs apoptosis’},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2024},
doi = {10.1136/jitc-2023-007983}
}
EUVIMED